Enoxaparin sodium

Research use only, not for human use.

Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI).

Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI). It binds to and potentiates the action of antithrombin, and inhibits coagulation factors XIa, IXa, Xa and IIa (thrombin), thereby preventing formation of blood clots.

Enoxaparin (0-70 μg/mL, 90 min) enhances AAT (alpha-1-antitrypsin) inhibition of both TMPRSS2 (Transmembrane Protease 2) activity and infection of hAEc (human airway epithelial cells) with HCoV-229E. Cell Viability Assay Cell Line:HEK293T TMPRSS2 cells, hAEc Concentration:0, 8.8, 35, 70 μg/mL Incubation Time:90 min Result:Significantly inhibited TMPRSS2 activity at the 90 min incubation period at 35 and 70 μg/mL, enhanced AAT inhibition of TMPRSS2 activity, and augmented AAT inhibition of HCoV-229E infection of hAEc.

Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat. Animal Model:Adult male Wistar rats (350-450 g, TBI-treated)Dosage:0 mg/kg, 1 mg/kg Administration:SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction.Result:Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active caspase-3 over expressions as well as neuro degeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat.

——

Autophagy

Thrombin

Parasite|N-myristoyltransferase-1 (NMT-1)

——

——

679809-58-6

1322

C42H59N3Na4O35S2

>98% (HPLC)

In Vitro:?H2O : ≥ 100 mg/mL

[Na+].[Na+].[Na+].[Na+].C[C@@H]1[C@@H](NC(C)=O)[C@@H](OC2[C@H](O)[C@@H](O)[C@H](OC3[C@H]4CO[C@H](O4)[C@H](NS([O-])(=O)=O)[C@H]3O)OC2C([O-])=O)O[C@H](CO)[C@H]1O[C@@H]1CC([C@@H](O[C@H]2O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]3OC(=C[C@H](O)[C@H]3O)C([O-])=O)[C@H](

——

(-20℃)

With Ice Pack

≥ 2 years